Press Releases

Press Releases

Year
News

02 April, 2020

Incyte Announces Plans to Initiate a Phase 3 Clinical Trial of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm

26 March, 2020

Incyte Names New Member to Its Board of Directors

24 March, 2020

Data from Phase 3 TRuE-AD Trials of Ruxolitinib Cream in Atopic Dermatitis to be Presented at the 2020 Revolutionizing Atopic Dermatitis Virtual Conference

16 March, 2020

Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata

03 March, 2020

MorphoSys and Incyte Announce Antitrust Clearance of Global Collaboration and License Agreement for Tafasitamab

27 February, 2020

Incyte Partners with Artist and Patient J.G. Jones to Raise Awareness for Myeloproliferative Neoplasms (MPNs)

19 February, 2020

Incyte Announces Launch of the Incyte Ingenuity Award Program to Recognize Innovation Within the GVHD Community

19 February, 2020

Incyte Announces Positive Topline Results From Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients With Atopic Dermatitis

13 February, 2020

Incyte Reports 2019 Fourth Quarter and Year-End Financial Results and Provides 2020 Financial Guidance and Updates on Key Clinical Programs

11 February, 2020

Incyte to Present at Upcoming Investor Conference

of 1 2 Next page
 

For Media Inquiries

Catalina Loveman
Executive Director, Public Affairs

+1 302.498.6171 | media@incyte.com


For Investor Relations

Michael Booth, D.Phil.
Divisional VP of Investor Relations and Corporate Responsibility

Phone: 302.498.5914

Email: mbooth@incyte.com

Lauren Ayala, MBA
Senior Director, Investor Relations & Corporate Responsibility

Phone: 302.498.6141

Email: layala@incyte.com

Christine Chiou
Senior Director, Investor Relations

Phone: 302.274.4773

Email: cchiou@incyte.com